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Abstract
Background: Administrative data can serve as an easily available source for epidemiological and
evaluation studies. The aim of this study is to evaluate the use of hospital administrative data to
determine breast cancer severity and the appropriateness of surgical treatment.
Methods: the study population consisted of 398 patients randomly selected from a cohort of
women hospitalized for first-time breast cancer surgery in the Lazio Region, Italy. Tumor severity
was defined in three different ways: 1) tumor size; 2) clinical stage (TNM); 3) severity indicator
based on HIS data (SI). Sensitivity, specificity, and positive predictive value (PPV) of the severity
indicator in evaluating appropriateness of surgery were calculated. The accuracy of HIS data was
measured using Kappa statistic.
Results: Most of 387 cases were classified as T1 and T2 (tumor size), more than 70% were in stage
I or II and the SI classified 60% of cases in medium-low category. Variation from guidelines
indications identified under and over treatments. The accuracy of the SI to predict under-treatment
was relatively good (58% of all procedures classified as under-treatment using pT where also
classified as such using SI), and even greater predicting over-treatment (88.2% of all procedures
classified as over treatment using pT where also classified as such using SI). Agreement between
clinical chart and hospital discharge reports was K = 0.35.
Conclusion: Our findings suggest that administrative data need to be used with caution when
evaluating surgical appropriateness, mainly because of the limited ability of SI to predict tumor size
and the questionable quality of HIS data as observed in other studies.
Background
Breast cancer is a major cause of cancer death among
women in the region of Lazio (central Italy, including
Rome), and in all of Italy [1,2]. Several randomized clini-
cal studies have shown that simple mastectomy is as effec-
tive as more radical treatment (Halsted's radical
mastectomy) in terms of survival [3,4]. Although national
and international guidelines list treatment protocols spe-
cific to the tumor's stage [5,6], the degree of adherence to
these guidelines in Italy is not known, and in recent years
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the surgical techniques for breast cancer used in different
Italian hospitals have varied widely [7,8]. Clinical stage is
the principal determinant of surgical treatment; specifi-
cally, there has been an under-use of conservative proce-
dures with stage I and II tumors [9]. Stage I (up to 2 cm in
diameter) and stage II tumors (more than 2 cm in diame-
ter) can be treated with conservative surgical intervention
(lymphoadenectomy and quadrantectomy) as effectively
as with radical mastectomy [10,11].
In Italy, regional hospital information systems (HIS) con-
tain information on all hospital admissions. They are a
valuable source of data for verifying the quality and
appropriateness of health procedures and/or in evaluating
the economic impact and frequency of use of new tech-
nology [12,13]. Current literature which uses HIS data to
evaluate breast cancer surgery is limited to geographic and
temporal variability of various surgical procedures and
their possible determinants [14,15]. A recent study con-
ducted in Australia described geographical variations in
surgical treatments offered to women with breast cancer
[16], while an American study showed that conservative
treatment is most common among young women, and
more frequently performed in university hospitals [17].
Data analyses from the London Tumor Registry showed
noticeable differences in therapeutic procedures in the 42
hospitals involved in the 1980's study [18]. Age and edu-
cation level appear to play important roles in the type of
surgical intervention offered [19]. A direct relationship
was observed between volume of hospital activity and
adherence to guidelines [20,21]. Various studies in Italy
also have documented levels of inappropriateness accord-
ing to hospital and patient characteristics [7,22]. In Lazio,
age, tumor severity and hospital volume were associated
with the use of conservative therapy [8].
HIS data have important limitations for breast cancer sur-
gery, mainly because they do not contain information on
tumor stage, available only in medical charts, the crucial
indicator for determining appropriate treatment, and
more generally, because administrative data completeness
and accuracy have not been established.
Despite the absence of tumour size in the HIS many
authors used the combinations of primary and secondary
ICD9-CM diagnosis to estimate breast cancer severity
[21,23].
The aims of this study are to: 1) validate a breast cancer
severity indicator (SI) calculated from primary and sec-
ondary diagnoses (ICD-9-CM codes) from the HIS; 2) ver-
ify the differences in the SI, tumor stage, and tumor size in
evaluating appropriateness of breast cancer surgery, and,
3) verify the accuracy and completeness of the HIS in
recording breast cancer diagnoses and surgical proce-
dures.
Methods
Study population
A sample of 398 hospital admissions were selected from a
Hospital Information System (HIS) based cohort of 4823
women with a principal diagnosis of breast cancer (ICD-
9-CM: 174.0–174.9) or of breast cancer in situ (ICD-9-
CM: 233.0), who were residents of the Lazio region,
(region of central Italy, including Rome, about 5 millions
inhabitants and 180 hospitals). and had their first surgical
intervention (ICD-9-CM: 85.20–85.25; 85.41–85.48)
between January 1997 and June 1998 in any one of the
regional hospitals. Patients were excluded if they had pre-
vious hospital admissions for malignant breast cancer
other than for diagnostic purposes.
Lazio region HIS
Since 1994 the HIS [24] has archived the data from hospi-
tal discharge records (HDR) of all Lazio regional hospi-
tals. The HDR summarizes information from clinical
charts regarding type of discharge, primary diagnosis, up
to three secondary diagnoses and four surgical, diagnostic
or therapeutic procedures, codified according to the Inter-
national Classification of Disease and Causes of Death
(ICD-9, 9a revision) [25].
Data source
For each hospital admission a photocopy of the original
clinical documents was requested. Three physicians, who
were also experts in classification systems and disease cod-
ifying, re-examined the clinical charts and reported rele-
Table 1: Classification of breast cancer according to the severity indicator (SI)
Categories description primary diagnosis secondary diagnosis
ICD9 -CM codes
1 In situ tumors 233.0 -
2 Localized tumors 174.0 – 174.9 -
3 Non-localized tumors 174.0 – 174.9; 233.0 196
4 Metastatitc tumors 174.0 – 174.9; 233.0 197; 198BMC Public Health 2006, 6:25 http://www.biomedcentral.com/1471-2458/6/25
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vant information onto a two part ad hoc schedule. The first
part requested both non-coded diagnoses and ICD-9-CM
coding from the HDR; the second part contained clinical
and anatomy-pathology parameters, including tumor size
(pT), and diagnostic results to calculate the stage of the
tumor (TNM) [5].
Definition of variables
A) Indicators of tumor severity
Tumor size
Size (pT) is classified into the following categories accord-
ing to pathology reports included in clinical charts: Tis for
carcinoma in situ/Paget, T0 for "no evidence" of a local
lesion; T1 for tumors up to 2 cm in diameter; T2 for
tumors from 2 to 5 cm; T3 for tumors greater than 5 cm,
and T4 for tumors that have spread into surrounding tis-
sue [5].
TNM staging system
The TNM stage was determined from clinical charts; this
defines five stages of breast cancer severity (from 0 to IV)
based on the size, but also on other characteristics of the
tumor, positive lymph nodes, and other sites of metastasis
[5]. Consequently, some categories correspond to tumor
size, while others do not. For example, a tumor up to 2 cm
in size (T1) with positive lymph-nodes is equivalent to a
bigger tumor (>T1) without positive lymph nodes.
Severity indicator (SI) based on the HIS diagnosis
The severity indicator we used is a modified version of the
indicator defined by Kahn et al [23], based on specific
ICD9 codes for breast cancer. It allows breast cancer cases
to be classified into 4 levels of clinical severity, from the
primary and secondary diagnoses reported in the HIS
(table 1). First level (I): tumors in situ; second level (II):
localized tumors; third level (III): non-localized tumors with
loco-regional metastasis; IV: non-localized tumors with distant
metastasis. The SI groups tumors according to their princi-
pal characteristics (localized/not-localized; presence/
absence of metastasis) like the TNM system, but does not
include tumour size(pT).
B) Indicators of intervention appropriateness
We referred to treatment Italian guidelines for breast can-
cer [5], which indicate
- conservative surgery for tumors up to 2 cm (for at least
80% of cases);
- Halsted mastectomy only for tumors that have infiltra-
tion of the thoracic wall;
- radical excision of auxiliary lymph nodes (or possibly
the search for sentinel lymph nodes in accredited hospi-
tals) in all cases except for tumors in situ.
According to the above criteria and to the review of clini-
cal charts interventions which varied from these indica-
tions were classified as "under-treatments" or "over-
treatments". Table 2 shows the definitions of over- and
under- treatment using the three aforementioned indica-
tors of tumor severity (pT, TNM, SI).
Data analysis
The agreement between SI and TNM classifications and
between SI and pT classifications (Intraclass correlation
coefficient, Spearman's Rho) [26] were determined. We
compared their ability to classify the appropriateness of
Table 2: Under and over-treatment categories used for the evaluation of appropriateness
pT Surgery 
procedures
Linfoadenectomy Stage SI
Under-treatment
T1 T2 T3 85.2* no I IIa IIb IIIa IIIb IV 2 3 4
Case a) T1 T2 T3 85.41–85.42 no I IIa IIb IIIa IIIb IV 2 3 4
T2 T3 85.2* yes IIa IIb IIIa IIIb 3 4
T4 85.2*, 85.41–85.44 IIIb 4
Over-treatment
Tis 85.4* yes 0 1
Tis 85.2* yes 0 1
Case b) T1 T2 T3 85.45–85.48 I IIa IIb IIIa IIIb 2 3
T1§ 85.41–85.44 I 2
§this case represents an over-treatment only if happens in more than 15% of the T1 cancers treated
Example:
a) case with tumor size T3, independently on the stage, who undergoes to intervention 85.41 (simple mastectomy) and no linfoadenectomy, is 
classified as under-treated
b) radical mastectomy (85.45–85.48) in a case with a tumor size less than T4, is always considered as an over-treatmentBMC Public Health 2006, 6:25 http://www.biomedcentral.com/1471-2458/6/25
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interventions, using pT as the gold standard for defining
"under-treated" and "over-treated" cases. The reason for
this choice is that pT is the only information surely avail-
able to every surgeons at the moment of choosing the
therapeutic intervention. Thus, sensitivity, specificity and
positive predictive values (PPV) were calculated respec-
tively for SI and TNM staging.
Lastly, we evaluated the accuracy of the data from the HIS
by measuring the agreement between the SI calculated
from the ad hoc schedule and from the clinical charts,
through a weighted kappa statistic. The PPV of the HIS
was also calculated.
Data were analyzed using SPSS [27].
Results
Clinical charts were obtained for 387 of the 398 cases
included in the sample (97.2 %). Sixty cases (Eleven cases
according to SI and 53 according to TNM stage and pT)
could not be assessed, due to unclear or incomplete
charts. According to the SI indicator, most of the cases had
a medium-low level of severity (about 66% in class 2).
Based on the TNM, more than 70% of cases were classified
stage I or II; based on pT, most cases (48.1%) were classi-
fied as T1 (Table 3).
A positive correlation (ρ = 0.6; p < 0.001) was observed
between the severity indicators SI and TNM and the distri-
Distribution of tumor stage by severity index Figure 1
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Table 3: Cases distribution according to the three classifications (pT, TNM, SI)
pT TNM SI
n% n% n%
Tis 11 2.8 0 13 3.4 1 15 3.9
T0 20 . 5I 146 37.7 2 257 66.4
T1 186 48.1 II 131 33.9 3 102 26.4
T2 97 25.1 III 40 10.3 4 20 . 5
T3 71 . 8 IV 41 . 0 missing 11 2.8
T4 31 8.0 missing 53 13.7 missing 53 13.7
total 387 100 total 387 100 total 387 100BMC Public Health 2006, 6:25 http://www.biomedcentral.com/1471-2458/6/25
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bution of tumor stage in each category of the SI, showed
in Figure 1, suggest a rather good agreement between the
two classifications. However, SI did not correlate as well
with pT size (ρ = 0.3 p < 0.001). In fact in class 1 of the SI
77% of tumors were size Tis and 15% were size T1, in class
2 66% were T1 and 24% T2, in class 3 37% were T1, 44%
T2 and 14% T4. Because only two cases belonged to class
4 the percentage was not calculable.
Based on pT, 28 % (94/334) of cases were under-treated
and 5% (17/334) were over-treated; based on TNM stage,
the percentages were 35% (117/334) and 5% (18/334)
and on the SI they were 25% (82/334) and 6% (19/334)
respectively (Table 4). The SI and pT (gold standard)
agreed relatively well in classifying "under"- and "over-
treated" cases (kappa = 0.53). The agreement between the
"under" and "over-treated" cases classified on the basis of
the TNM and tumor size pT was very high (kappa = 0.82).
The accuracy of the SI in estimating under-treatment was
fair (58% of all procedures classified as under-treatment
using pT where also classified as such using SI; 67.1% of
all procedures classified as under-treatment using SI
where classified as such according to pT), while it was
quite good for over-treatment (respectively 88.2% and
78.9%). The TNM staging system showed values of 96.8%
and 77.8% for under-treatment and 100% and 94.4% for
over-treatment (Table 4).
Lastly, the total agreement between HIS data and clinical
charts was quite low (kappa = 0.35) and the PPVs (Table
5) were 11% for class 1, 75% for class 2 and 76% for class
3. Class 1, tumors in situ, in particular showed very low
PPVs. A misclassification was observed for tumors in situ
by the HIS; it misclassified 8 invasive tumors as cancer in
situ, and failed to identify 14 out of 15 of them. As a result,
67 cases were listed as "localized tumors" in the HIS but
as "non-localized" on the clinical chart.
Discussion
The study indicates that with data from hospital discharge
reports it is possible to construct an indicator of breast
tumor severity that performs quite well compared to clin-
ical and histological classifications. However, it needs to
be used with caution in estimating the appropriateness of
Table 4: Agreement between SI – pT and TNM-pT for under- and over-treatment. Standard of reference: pT.
Under treatment
pT
yes no tot
n col% row% n col % row%
SI yes 55 58,5 67,1 27 11,3 32,9 82
no 39 41,5 47,6 213 88,8 84,5 252
tot 94 100,0 240 100,0 334
pT
yes no tot
n col% row% n col % row%
TNM yes 91 96,8 77,8 26 10,8 22,2 117
no 3 3,2 1,4 214 89,2 98,6 217
tot 94 100,0 240 100,0 334
Over treatment
pT
yes no tot
n col% row% n col % row%
SI yes 15 88,2 78,9 4 1,3 21,1 19
no 2 11,8 0,6 313 98,7 99,4 315
tot 17 100,0 317 100,0 334
pT
yes no tot
n col% row% n col % row%
TNM yes 17 100,0 94,4 1 0,3 5,6 18
no 0 0,0 0,0 316 99,7 100,0 316
tot 17 100,0 317 100,0 334
In bold are sensitivity (col% of yes), specificity (col% of no) and PPV (row% of yes)BMC Public Health 2006, 6:25 http://www.biomedcentral.com/1471-2458/6/25
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surgical treatment, because although it is sufficiently thor-
ough in estimating over-treated cases, it tends to underes-
timate under-treatment. The validity of the severity
indicator from the HIS depends explicitly on the com-
pleteness and quality of the data.
Our proposed indicator is based on ICD-9-CM codes of
breast cancer diagnoses and procedures, and uses some of
the criteria proposed by Kahn et al in 1996 [23]. Since the
ICD-9-CM coding does not include tumor size, their indi-
cator is based on the assumption that there is a positive
correlation between the extent of the growth (localized,
loco-regional, and distant) and the size of the tumor.
Consequently, the criteria were based on the level of dif-
fusion of the tumor from the ICD-9-CM codes, which
served as a proxy for tumor size, and thus for severity.
Kahn et al evaluated the accuracy of ICD-9-CM codes in
correctly identifying localized breast cancer, and then in
documenting the percentage of lymphoadenectomies that
had been performed, comparing to the data from the can-
cer register. The authors calculated the raw agreement of
the two information sources was 82%; the sensitivity and
specificity was acceptable (above 85%). Thus, the data
from the HIS were considered valid in evaluating appro-
priateness of surgery typology according to tumor severity
(localized/not localized), but not for analyzing therapeu-
tic outcomes[23]. Our study modified Kahn's SI to better
differentiate degrees of severity: we considered cancer in
situ as a category in and of itself (otherwise included in the
same category with localized tumors) and we distin-
guished, in the non-localized tumor category, those with
loco-regional metastasis from those with distant metasta-
sis. A similar approach is found in the study conducted by
Rohan et al [21].
The correlation of the SI with TNM stages was rather good
(0.6; p < 0.001), but not as good with tumor size (pT)
(0.3; p < 0.001). These results suggest that the SI can be
considered an adequate proxy of tumor severity, but is not
as precise an indicator of tumor size. Unfortunately,
tumor size is usually the only indicator available to physi-
cians when determining treatment.
We also evaluated the possibility of using the SI to evalu-
ate appropriateness of treatment: the SI appears to classify
cases of over-treatment relatively well but underestimates
under-treated cases. We found that TNM and pT classifica-
tions are better indicators of under- and over-treatment;
this may be because size is a component of TNM staging.
It is, however, important to note that the SI seems a con-
servative indicator of both over-treatment and under-
treatment, minimizing the risk of inappropriately catego-
rizing difficult cases.
In order to rule out possible errors of classification, codi-
fication or input, data registered on an ad hoc schedule
were used instead of the original HIS information to con-
struct the SI. Subsequently however, the completeness
and accuracy of the discharge reports were assessed com-
paring them to clinical documents: this study was a part of
a larger study on quality of data from HIS, methods and
results are available on technical report published on web
[28]Hospital discharge records have been shown to have
problems of under-notification of health data, which
greatly decrease their value to analytic studies, [29,30].
Furthermore, in our study there were a number of cases
for which it was not possible to define the TNM stage due
to lack of information on the clinical documents, which
could have in part reduced the "validity" of our gold
standard. The PPV of the HIS is overall quite low (Kappa
= 0.35), mainly due to a high level of discordance in the
first SI category (carcinoma in situ). The PPV in the other
three categories comparatively is rather good.
Table 5: Validity of HIS data necessary to calculate the SI
Si calculated from HIS data
ca in situ localized not-localized matastatic total
n%n%n%n%n
SI calculated 
from CC
ca in situ 1 11,1 14 4 0 0 0 0 15
localized 5 57 240 75 10 24 0 0 255
not-localized 3 33 67 21 31 76 0 0 101
metastatic 0 0 0 0 0 0 2 100 2
total 9 100 321 100 41 100 2 100 373
Kappa= 0.35
p < 0.00
values in bold represent the positive predictive valueBMC Public Health 2006, 6:25 http://www.biomedcentral.com/1471-2458/6/25
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Conclusion
Our findings support previous literature results that hos-
pital discharge reports are potentially utilizable to define
the clinical severity of breast cancer, mainly for the pur-
pose of public health evaluations, such as studying varia-
tions in breast cancer treatment in key demographic
groups. The limited ability of SI to predict tumor size and
the questionable quality of HIS data do not support the
use of this indicator to evaluate clinical outcomes or
appropriateness of surgical treatments for breast cancer.
Improvement of HIS coding accuracy and completeness
could make it possible the use of administrative data for
epidemiological purposes.
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